Searching the Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Nasopharyngeal carcinoma (NPC) is one of the most commons cancers in Southeast Asia and Southern China. Several NPC-associated genes have been so far described and here we describe the identification and the characterization of a novel nasopharyngeal carcinoma-associated peptide: NAP-1. NAP-1 was identified with the human genome draft searching method combined with nested PCR mapping of the chromosome 4q13 region. NAP-1 encodes an 85 amino acid alkaline peptide with a calculated isoelectric point of 9.3, three phosphorilation sites and a proline-rich region. Northern blot analysis revealed that NAP-1 is expressed as a 0.6 kb transcript in normal lymph nodes and trachea. In addition, reverse transcription (RT)-PCR showed that NAP-1 is expressed not only in NPC but in normal nasopharynx (NP) and various other tumors and tissues of the head and neck including: tonsils, lymph nodes, carcinoma of the tonsil, T cell lymphomas, squamous cell carcinoma of the hard palate, papilloma of the nasopharynx, nasopharyngitis, lymphoma of the tongue root and follicular dendritic cells (FDC). In addition, NAP-1 is not expressed in normal tissues or tumors from other anatomical regions and was not expressed by NPC cell lines. Surprisingly, differential RT-PCR demonstrated decreased expression of NAP-1 in NPC compared with paired NP biopsies in 42.5 % of cases (17 out of 40). In addition, in situ hybridization and immunohistochemistry demonstrated that NAP-1 is expressed by S100+ CD35+ FDCs of the germinal center and not in other normal immune cells infiltrating NP or NPC. Therefore, it is likely that NAP-1 is secreted by FDC in the NP and may play an immune modulatory role in NPC.
Pubmed ID: 15070408
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
A portal to educate, engage and create an online community. The Fisher Center for Alzheimer''s Research Foundation, founded in 1995, was created in answer to the recommendations of three U.S. Senate commissioned symposia held in the 1990s by the National Institutes of Health (NIH) to gather information on the cause, care and cure of Alzheimer''s disease. The Fisher Center was created following this design. The funding initiatives of the Foundation are appropriated accordingly to the three areas cited by the NIH task force cause, care and cure. The primary resources of the Foundation are directed toward scientific research into the cause and hopefully the cure of Alzheimer''s disease. To this end, the Foundation under the direction of its founder, Zachary Fisher, and in collaboration with David Rockefeller, constructed the Fisher Center for Alzheimer''s Disease Research at The Rockefeller University, headed by 2000 Nobel Prize winner, Paul Greengard, Ph.D. The 10,000 square foot laboratory is the most advanced facility of its kind in the country equipped with the latest in equipment necessary to undertake an interdisciplinary assault on this disease. The Fisher Center also has collaborative programs at the University of Genoa and supports the work of well over 60 scientists and researchers across the United States and in 17 foreign countries. The Foundation also funds projects for the care of people with Alzheimer''s disease and their caregivers. The Fisher Alzheimer''s Disease Education and Resources Program at the New York University School of Medicine was established under the direction of Barry Reisberg, M.D., internationally known expert in the care of Alzheimer''s patients. The Foundations Alzheimer''s Information Program was created in 2001 to answer the primary need of caregivers for comprehensive, easily accessible information. Our goals are to: Understand the Cause of Alzheimer''s To find a Cure for this devastating disease Improve the Care of people living with the disease to enhance their quality of life and that of their caregivers and families About Our Research Beating Back Beta Amyloid Improving the Quality of Life for Alzheimers Patients Reversing Nerve Cell Damage Using Hormones to Slow the Progress of Disease Curing Early-Onset Alzheimers The Science of Caregiving Scientific Studies
View all literature mentions